

Curriculum vitae

Christian Hampp, Ph.D., B.S. Pharm.

Address: U.S. Food and Drug Administration
10930 New Hampshire Ave
Silver Spring, MD, 20993
Phone: (301) 796-7648
Email: christian.hampp@fda.hhs.gov

Place of birth: Neunkirchen/Saar, Germany
Citizenship: United States, Germany

Current Position

Since 12/2017 **Master Reviewer Epidemiologist**
Division of Epidemiology-I
Office of Pharmacovigilance and Epidemiology
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

2/2016-12/2017 **Senior Epidemiologist**
FDA/CDER/OSE/OPE/DEPI-I

5/2012 – 2/2016 **Senior Staff Fellow**
FDA/CDER/OSE/OPE/DEPI-I

8/2010 - 5/2012 **Visiting Associate**
FDA/CDER/OSE/OPE/DEPI-I

Since 1/2011 **Affiliate Clinical Assistant Professor**
Graduate Faculty Member
Pharmaceutical Outcomes and Policy
College of Pharmacy
University of Florida

Short Bio

After finishing pharmacy school in Saarbrücken, Germany, Dr. Hampp joined the Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, where he graduated with a PhD in pharmacoepidemiology in August, 2009. Following a year of post-doctoral studies at UF, he joined FDA's Office of Surveillance and Epidemiology, Division of Epidemiology, in August 2010 as a Visiting Associate. He is now a Master Reviewer Epidemiologist working in the fields of metabolic and endocrine drugs. In this position, he works with pharmacists, medical officers, team leaders, division and office directors, safety evaluators, regulatory project managers, biostatisticians, and communications specialists inside and outside the division and provides his expertise in pharmacoepidemiology to support complex decisions. He has conducted reviews of the medical literature, provided recommendations on study protocols, reviewed study results, and recommended regulatory action, when indicated. Several of his reviews have resulted in labeling

changes and issuance of Drug Safety Communications. Dr. Hampp presented his reviews at multiple Advisory Committee meetings where he represented FDA as an expert in pharmacoepidemiology. FDA has recognized his contribution to the public health mission with multiple individual and group awards. As a researcher, he received professional recognition through his published research and award-winning presentations at international meetings. He currently serves as the CDER liaison to the Board of Directors of the International Society for Pharmacoepidemiology. Internally, Dr. Hampp presented to the Division of Epidemiology on complex methodological issues in cancer pharmacoepidemiology, and lectured to FDA colleagues about epidemiologic methods and FDA's pharmacoepidemiology guidance. Externally, he has lectured repeatedly about postmarketing drug safety at the FDA. He is also an Affiliate Clinical Assistant Professor and member of the graduate faculty at the University of Florida. Finally, he serves as member of FDA's Committee for Advanced Scientific Education and its Seminar subcommittee.

Professional Experience

- 8/2009 - 7/2010 **Post-Doctoral Associate**
Pharmaceutical Outcome and Policy, College of Pharmacy, University of Florida
- 8/2004 - 8/2009 **Graduate Teaching Assistant**
Pharmaceutical Outcome and Policy, College of Pharmacy, University of Florida
- 11/2003 – 5/2004 **Intern**
Insel-Apotheke, Berlin, Germany
- 5/2003 – 11/2003 **Intern**
Pharmaceutics, College of Pharmacy, University of Florida, including 6 weeks in Drug Information Center
- 3/2000 - 4/2000 **Intern**
Hoffmann – La Roche AG, Grenzach-Wyhlen, Germany
- Summer 1999 **Intern**
Adler Apotheke, St. Ingbert, Germany

Education

- 8/2004 - 8/2009 **University of Florida**, College of Pharmacy, Pharmaceutical Outcomes and Policy
Doctor of Philosophy, GPA 3.95
Dissertation: "Utility of Current Surveillance Systems to Detect Respiratory Syncytial Virus Seasons and Implications for Immunoprophylaxis"
Advisor: Dr. Almut Winterstein
- 6/2004 **Saarland State Board of Pharmacists**, Saarbrücken, Germany,
State Board Examination, degree: Apotheker (~RPh)

- 1999 – 2003 **Saarland University**, Saarbrücken, Germany
College of Pharmacy, degree: B.S. Pharm.
- 1998 – 1999 **German Red Cross**, St. Ingbert, Germany
Ambulance driver training; 520 hours of training including practical
experience in intensive care and anesthesiology at the local county hospital

Teaching Experience

FDA

- Since 2016 **Member**, FDA Committee for Advances Clinical and Scientific Education
(CACSE)
- 2011 - 2017 **Faculty**, Epidemiology in Drug Safety: Measures of Association/Causality
2016 **Faculty**, Training for FDA Pharmacoepidemiology Guidance

American Society of Health System Pharmacists (ASHP) Foundation

- 2013 - 2016 **Faculty**, ASHP Research Boot Camp

International Society for Pharmacoepidemiology (ISPE)

- 2014 - 2018 **Faculty**, Practical Skills in Protocol Writing and Computer Programming

University of Florida

- 2012 - 2015 **Instructor**, Online course: Introduction to Pharmacoepidemiology
2009 **Instructor**, Online course: Evidentiary Basis of Pharmaceutical Use
2005 - 2008 **Teaching Assistant, Senior Teaching Assistant, Assistant Course
Coordinator**, Evidence Based Pharmacy,
2005 - 2008 **Teaching Assistant**, Professional Communications
2005 - 2009 **Preceptor**, Working Professional PharmD Program
- Medication history
 - Patient assessment

Mentoring

Dissertation Committees

- Caitlin Knox, Ph.D., M.P.H., University of Florida, Graduation 8/2014. Thesis: “The Comparative Safety of Anti-Diabetic Treatment in Pregnant Women with Pre-Existing Diabetes”
- Yanmin Zhu, University of Florida
- YoonYoung Choi, University of Florida

FDA

- Robert Campbell, Ph.D., Epidemiologist, 2014
- Caitlin Knox, Summer Intern at FDA, 2012
Project: “Patient Understanding of Drug Risks: Analysis of Medication Guide Assessments”

Scientific Achievements

Honors, Awards, and Fellowships

- **FDA-CDER Team Excellence Award**, Epidemiology in Drug Safety Course Faculty, 2017.
- **FDA-CDER Regulatory Science Team Excellence Award**, Synthesizing Data from Observational Studies Collaboration, 2016.
- **FDA-CDER Regulatory Science Excellence Individual Award**, 2015.
- **FDA-CDER Team Excellence Award**, Epidemiology team for metabolic and endocrine drugs, 2014.
- **FDA Group Recognition Award**, Sentinel Initiative development team, 2012.
- **FDA-CDER Frances O. Kelsey Drug Safety Excellence Award**, Epidemiology in Drug Safety education group, 2012.
- **FDA-CDER Regulatory Science Excellence Individual Award**, 2012.
- **First Place – ICPE Poster Walk, Drug Utilization SIG**, Timing of Prophylaxis Relative to Respiratory Syncytial Virus Seasons. **Hampp C**, Winterstein AG. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Brighton, UK, August 19-22, 2010. *Pharmacoepidemiol Drug Saf* 2010; **19**:S201-202
- **Best Student Research Poster Presentation**, Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab from the Perspective of a Southern US Medicaid Agency. **Hampp C**, Kauf TL, Saidi A, Winterstein AG. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009. *Value Health* 2009; **12 (7)**:A301
- **Finalist, Poster Competition**, Seasonal versus Needs-Based Immunization Schedules – the Example of RSV. **Hampp C**, Winterstein AG. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009. *Value Health* 2009; **12 (7)**:A307
- **University of Florida Graduate Student Teaching Award 2008-2009**, Award: \$500
- **Winner, Oral Competition**, College of Pharmacy, University of Florida, 22nd annual research showcase, Feb, 19, 2009, Levitt Division. **Hampp C**, Winterstein AG, Saidi A. Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab from the Perspective of Florida Medicaid. Award: \$600
- **Best Drug Utilization Abstract Submitted by a Student**: Palivizumab Utilization and Compliance with Recommendations in Florida. **Hampp C**, Winterstein AG. 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Copenhagen, Denmark, August 17-20, 2008. *Pharmacoepidemiol Drug Saf* 2008;**17**:S25 (oral presentation)
- **Winner, Best Poster Award**, College of Pharmacy, University of Florida, 21st annual research showcase, Feb, 21, 2008: **Hampp C**, Winterstein AG, Saidi A. Palivizumab Utilization and Compliance – The Current State of Respiratory Syncytial Virus Prophylaxis in Florida. Award: \$300
- First honorary recipient of the **DuBow Family Fellowship for Pharmaceutical Outcomes and Policy Research**
- **Teaching Assistant Award 2006**, Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida. Award: \$2,000

- Award for **Outstanding Academic Achievement by an International Student**, College of Pharmacy, University of Florida, April 2006
- **Finalist, Oral Competition**, College of Pharmacy, University of Florida, 19th annual research showcase, Levitt Division, Feb, 23, 2006: **Hampp C**, Hartzema AG. Cost-Utility of Rimonabant in the Treatment of Obesity. Award: \$300
- **Grinter Fellowship**, University of Florida, from 2004 – 2007: total \$9,000

Grants

1. **Effectiveness of Palivizumab in Older Infants.** Investigator, PI: Almut Winterstein, 7/1/08 – 6/30/10. Florida Department of Health, Agency for Healthcare Administration. \$269,772
2. **RSV Seasonality in Florida and Recommendations for Timing of Immunizations.** (provided funding for dissertation) Investigator, PI: Almut Winterstein, 7/1/08 – 6/30/10. Florida Department of Health, Agency for Healthcare Administration. \$199,337
3. **Once-Daily versus Twice-Daily Enoxaparin for Venous Thromboembolism Prophylaxis in High-Risk Trauma Patients.** Investigator, PI: Sarah Bush, 07/2007 – 07/2008. ASHP Foundation Pharmacy Resident Practice-Based Research Grant, \$5,000
4. **Palivizumab Utilization, Effectiveness and Cost among Florida Medicaid recipients.** Investigator, PI: Almut Winterstein, 1/1/07 – 7/31/2008. Florida Department of Health, Agency for Healthcare Administration. \$241,397

Bibliography

Peer Reviewed Articles

1. Illoh OA, Toh SD, Andrade SE, **Hampp C**, Sahin L, Gelperin K, Taylor L, Bird ST. Utilization of Drugs with Pregnancy Exposure Registries during Pregnancy. *Pharmacoepidemiol Drug Saf.* 2018. ePub March 2018.
2. Toh S, Reichman ME, Graham DJ, **Hampp C**, Zhang R, Iyer A, Rucker M, Pimentel M, Hamilton J, Fireman B, for the Mini-Sentinel AML-Saxagliptin Surveillance Workgroup. Prospective post-marketing surveillance of acute myocardial infarction in new users of saxagliptin. *Diabetes Care.* 2018 Jan; **41(1)**:39-48.
3. Gagne JJ, Houstoun M, Reichman ME, **Hampp C**, Marshall, JH, Toh S. Safety assessment of niacin in the US Food and Drug Administration's Mini-Sentinel system. *Pharmacoepidemiol Drug Saf.* 2018; **27**:30–37.
4. Bird ST, Gelperin K, Taylor L, Sahin L, Hammad H, Andrade AE, Mohamoud M, Toh SD, **Hampp C**. Enrollment and Retention in 34 United States Pregnancy Registries Contrasted with the Manufacturer's Capture of Spontaneous Reports for Exposed Pregnancies. *Drug Saf.* 2018; **41(1)**:87-94. (with Editorial)
5. McCarren M, **Hampp C**, Gerhard T, Mehta S. Recommendations to the Use and Nonuse of the P-Value in Biomedical Research. *Am J Health-Syst Pharm.* 2017; **74**:1262-6.
6. Zhou M, Wang SV, Leonard CE, Gagne JJ, Fuller C, **Hampp C**, Archdeacon P, Toh S, Iyer A, Woodworth TS, Cavagnaro E, Panozzo CA, Axtman S, Carnahan RM, Chrischilles EA,

Hennessy S. Sentinel Modular Program for Propensity-Score Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia. *Epidemiology*. 2017 Nov; **28(6)**:838-846.

7. **Hampp C**, Pippins, J. Pioglitazone and Bladder Cancer: FDA's Assessment. *Pharmacoepidemiol Drug Saf*. 2017 Feb; **26**:117-118.
8. Gelperin K, Hammad H, Leishear K, Bird ST, Taylor L, **Hampp C**, Sahin L. A Systematic Review of Pregnancy Exposure Registries: Examination of Protocol-specified Pregnancy Outcomes, Target Sample Size, and Comparator Selection. *Pharmacoepidemiol Drug Saf*. 2017 Feb; **26**:208-214.
9. Budnitz DS, Lovegrove MC, Sapiano MR, Mathew J, Kegler SR, Geller AI, **Hampp C**. Notes from the Field: Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion - United States, 2008–2015. *MMWR Morb Mortal Wkly Rep* 2016; **65**:1148-1149.
10. Toh S, **Hampp C**, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, Hamilton J, Lendle S, Iyer A, Rucker M, Pimentel M, Nathwani N, Griffin MR, Brown NJ, Fireman BH. Hospitalized Heart Failure Outcomes in New Users of Antihyperglycemic Drugs. *Ann Intern Med*. 2016; **164**:705-714. (with Editorial)
11. **Hampp C**, Greene P, Pinheiro SP. Use of Prescription Drug Samples in the USA and Implications for Pharmacoepidemiologic Studies. *Drug Saf*. 2016 Mar; **39(3)**:261-70.
12. Knox C, **Hampp C**, Willy M, Winterstein AG, Dal Pan G. Patient Understanding of Drug Risks: Analysis of Medication Guide Assessments. *Pharmacoepidemiol Drug Saf*. 2015; **24**:518–25.
13. Lovegrove MC, Mathew J, **Hampp C**, Governale L, Wysowski DK, Budnitz DS. Emergency Hospitalizations for Unsupervised Ingestion of Prescription Medications by Young Children. *Pediatrics*. 2014 Oct; **134(4)**:e1009-16.
14. **Hampp C**, Borders-Hemphill V, Money DG, Wysowski DK. Use of Antidiabetic Drugs in the United States, 2003-2012. *Diabetes Care*. 2014 May; **37(5)**:1367-74. (with Editorial)
15. Winterstein AG, Knox C, Kubilis PS, **Hampp C**. Appropriateness of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Moderate-Preterm Infants- A Cohort Study. *JAMA Pediatrics*. 2013 Dec; **167(12)**:1118-24.
16. **Hampp C**, Kang E, Borders-Hemphill V. Use of Prescription Antiobesity Drugs in the United States. *Pharmacotherapy*, 2013; **33(12)**:1299-1307.
17. **Hampp C**, Asal N, Lipowski EE, Kauf TL, Schneider EE, Kubilis PS, Winterstein AG. Validity of Laboratory Based Surveillance to Detect Respiratory Syncytial Virus Seasons. *Am J Epidemiol*. 2013 **177**: 841-51.
18. Lawrence JM, Andrade SE, Avalos LA, Beaton SJ, Chiu VY, Davis RL, Dublin S, Pawloski PA, Raebel MA, Smith DH, Toh S, Wang JQ, Kaplan S, Amini T, **Hampp C**, Hammad TA, Scott PE, Cheetham TC; for the Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) Study Group. Prevalence, Trends, and Patterns of Use of Antidiabetic Medications among Pregnant Women in the United States, 2001-2007. *Obstet Gynecol*. 2013 Jan; **121(1)**:106-14.
19. Irazuzta J, Egelund T, Wassil SK, **Hampp C**. Feasibility and Safety of Prolonged Magnesium Sulfate Infusion in Status Asthmaticus. *J Pediatr Pharmacol Ther*. 2012 Apr; **17(2)**:150-4.
20. Eworuke E, **Hampp C**, Winterstein AG. An Algorithm to Identify Preterm Infants in Administrative Claims Data. *Pharmacoepidemiol Drug Saf*. 2012 Jun; **21(6)**:640-50.

21. Winterstein AG, **Hampp C**, Saidi AS. Effectiveness of palivizumab in infants and children in Florida. *Pharmacoepidemiol Drug Saf.* 2012 Jan; **21(1)**: 53-60.
22. Pinney MF, Rosenberg A, **Hampp C**, Akindipe O, Schain D, Baz M. Invasive Fungal Infections in Lung Transplant Patients Without Routine Systemic Antifungal Prophylaxis: 12 Years Experience at a University Lung Transplant Center. *Pharmacotherapy.* 2011; **31(6)**: 537–45.
23. **Hampp C**, Kauf TL, Saidi AS, Winterstein AG. Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis for Various Indications. *Arch Pediatr Adolesc Med.* 2011 Jun; **165(6)**:498-505.
24. Park HS, **Hampp C**, Demer JL. Longitudinal Study of Optic Cup Progression in Children. *J Pediatr Ophthalmol Strabismus.* 2011 May; **48(3)**:151-6.
25. Bush S, LeClaire AC, **Hampp C**, Lottenberg L. Review of a large clinical series: once- versus twice-daily enoxaparin for venous thromboembolism prophylaxis in high-risk trauma patients. *J Intensive Care Med.* 2011 Mar-Apr; **26(2)**:111-5.
26. Dee AA, Kelly B, **Hampp C**. Root Cause Analysis and Subsequent Intervention to Improve First Dose Antibiotic Turnaround Time for Hospitalized Pediatric Patients. *J Pediatr Pharmacol Ther* 2010. **15 (3)**: 182-8.
27. **Hampp C**, Saidi A, Winterstein A. Palivizumab Utilization and Compliance – Trends in Respiratory Syncytial Virus Prophylaxis in Florida. *J Pediatr* 2010; **156**: 953-9.
28. **Hampp C**, Hartzema AG, Kauf TL. Cost-Utility Analysis of Rimonabant in the Treatment of Obesity. *Value Health.* 2008 May/June; **11 (3)**: 389–99.

Commentaries and Letters

29. Panozzo CA, **Hampp, C**. Can a reduced-dose prophylaxis schedule provide adequate coverage against respiratory syncytial virus infection? *Clin Infect Dis.* 2015 **61 (4)**: 515-516. (invited commentary)
30. **Hampp C**, Kauf TL, Saidi AS, Winterstein AG. Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaid-Reply. *Arch Pediatr Adolesc Med.* 2012 Oct 1; **166(10)**:968-970. (letter-response)
31. **Hampp C**, Kauf TL, Winterstein AG. Small budget impact is a result of flawed assumptions and ignores questionable cost-effectiveness for RSV prophylaxis. *Value Health.* 2010 Jul/Aug, **13(5)**: 684 (letter to the editor)
32. **Hampp C**, Winterstein AG. Response to Respiratory syncytial virus *South Med J.* 2008 Feb;**101(2)**:212-3 (letter-response)

Submitted, Accepted, or In Print Manuscripts

- Knox CA, **Hampp C**, Brumback B, Segal R, Winterstein AG. Epidemiology of Pre-existing Diabetes in Pregnancy among Medicaid Patients in 29 US States from 2000-2006 (submitted for publication)

Refereed Posters and Oral Presentations

1. Hou L, Cocoros N, **Hampp C**, Swain R, Maro JC. Type 1 and Type 2 Diabetes Mellitus Identification Using ICD-9-CM Codes within a Cohort of New Users of Drugs Labeled for Type 2 Diabetes Mellitus. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 26-30, 2017. *Pharmacoepidemiol Drug Saf*, 2017; **26**(Suppl. 2): 84.
2. Zhu Y, **Hampp C**, Wei YJ, Roussos-Ross D, Brumback B, Wang X, Albogami Y, Winterstein AG. Validation of Algorithms to Estimate Gestational Age in Medicaid Analytic eXtract Data. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 26-30, 2017. *Pharmacoepidemiol Drug Saf*, 2017; **26**(Suppl. 2): 436.
3. Zhou M, Wang SV, Leonard SE, Gagne JJ, Fuller C, **Hampp C**, Archdeacon P, Toh SD, Alyer A, Woodworth TS, Cavagnaro E, Panozzo C, Axtman S, Carnahan RM, Chrischilles EA, Hennessy S. Pilot Test of the Sentinel Modular Program for Propensity-Score Matched Cohort Analyses: Application to Glyburide, Glipizide, and Severe Hypoglycemia. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, August 25-28, 2016. *Pharmacoepidemiol Drug Saf*, 2016; **25**: S56. **First place, spotlight session: Databases**
4. Bird ST, **Hampp C**, Taylor L, Gelperin K, Reichman ME, Sahin L. A Systematic Review of Enrollment and Retention in US Pregnancy Exposure Registries and Corresponding Pharmacovigilance Systems. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, August 25-28, 2016. *Pharmacoepidemiol Drug Saf*, 2016; **25**: S298.
5. Bird ST, Taylor L, **Hampp C**, Sahin L, Toh SD, Andrade S, Haffenreffer K, Reichman ME, Gelperin K. Utilization Patterns of Drugs or Biologics with Pregnancy Exposure Registries in Pregnant and Matched Non-Pregnant Women in the Sentinel Database. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, August 25-28, 2016. *Pharmacoepidemiol Drug Saf*, 2016; **25**: S484.
6. Gelperin K, Hammad H, Bird S, **Hampp C**, Leishear K, Sahin L, Taylor L. Systematic Review of Pregnancy Exposure Registries: Fetal/Infant Outcomes, Target Sample Size, and Comparators. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA, August 22-26, 2015. *Pharmacoepidemiol Drug Saf*. 2015; **24**:S271.
7. Knox A, **Hampp C**, Brumback B, Xu X, Segal R, Winterstein AG. Risk of Cesarean Section Delivery among Live Births Exposed to Anti-Diabetic Agents during the First Trimester of Pregnancy. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA, August 22-26, 2015. *Pharmacoepidemiol Drug Saf*. 2015; **24**:S250.
8. Knox A, **Hampp C**, Brumback B, Xu X, Segal R, Winterstein AG. Risk of Preeclampsia among Live Births Exposed to Anti-diabetic Agents during the First Trimester of Pregnancy. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA, August 22-26, 2015. *Pharmacoepidemiol Drug Saf*. 2015; **24**:S249.
9. Knox A, **Hampp C**, Brumback B, Xu X, Segal R, Winterstein AG. Risk of Preterm Delivery among Live Births Exposed to Anti-diabetic Agents during the First Trimester of Pregnancy. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA, August 22-26, 2015. *Pharmacoepidemiol Drug Saf*. 2015; **24**:S249.
10. **Hampp C**, Greene P, Pinheiro SP. Use of Prescription Drug Samples in the United States and Implications for Pharmacoepidemiologic Studies. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA, August 22-26, 2015. *Pharmacoepidemiol Drug Saf*. 2015; **24**:S204.

11. Knox CA, **Hampp C**, Willy M, Winterstein AG, Dal Pan G. Patient Understanding of Drug Risk: Analysis of Medication Guide Assessments. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 25-28, 2013. *Pharmacoepidemiol Drug Saf.* 2013; **22**:S361.
12. **Hampp C**, Kang EM, Borders-Hemphill V. Use of Prescription Weight-Loss Drugs in the United States, 1993–2011. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 25-28, 2013. *Pharmacoepidemiol Drug Saf.* 2013; **22**:S470.
13. **Hampp C**, Borders-Hemphill V, Moeny DG, Wysowski DK. Utilization of Antidiabetic Drugs among U.S. Children and Adolescents, 2002–2011. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 25-28, 2013. *Pharmacoepidemiol Drug Saf.* 2013; **21**:S133.
14. **Hampp C**, Borders-Hemphill V, Moeny DG, Wysowski DK. Utilization of Antidiabetic Drugs among U.S. Adults, 2002–2011. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Barcelona, Spain, August 23-26, 2012. *Pharmacoepidemiol Drug Saf.* 2012; **21**:S282.
15. Knox CA, **Hampp C**, Kubilis PS, Linden S, Winterstein AG. Appropriateness of Age Thresholds for Palivizumab Prophylaxis in Preterm Infants. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago, IL, August 14-17, 2011. *Pharmacoepidemiol Drug Saf.* 2011; **20**:S252.
16. Winterstein AG, **Hampp C**, Kubilis PS, Saidi AS. Age-Dependent Effectiveness of RSV Immunoprophylaxis. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago, IL, August 14-17, 2011. *Pharmacoepidemiol Drug Saf.* 2011; **20**:S322-323.
17. **Hampp C**, Winterstein AG. Timing of Prophylaxis Relative to Respiratory Syncytial Virus Seasons. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Brighton, UK, August 19-22, 2010. *Pharmacoepidemiol Drug Saf.* 2010; **19**:S201-202. **First Place – ICPE Poster Walk, Drug Utilization SIG**
18. Odia E, **Hampp C**, Winterstein AG. Validity of an Algorithm for the Identification of Premature Infants Using Medicaid Administrative Data. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Brighton, UK, August 19-22, 2010. *Pharmacoepidemiol Drug Saf.* 2010; **19**:S123-124.
19. **Hampp C**, Saidi AS, Winterstein AG. Comparison of RSV Seasonality in Four States. Society of Epidemiologic Research 43rd Annual Meeting, Seattle, WA, June 23-26, 2010. *Am J Epidemiol.* 2010; **171(Suppl)**: S136.
20. **Hampp C**, Saidi AS, Winterstein AG. Latitude as a Factor in RSV Epidemiology in Florida. Society of Epidemiologic Research 43rd Annual Meeting, Seattle, WA, June 23-26, 2010. *Am J Epidemiol.* 2010; **171(Suppl)**: S136.
21. Park HJS, **Hampp C**, Demer JL. Longitudinal Study of Optic Cup Progression in Children. American Association of Pediatric Ophthalmology and Strabismus Annual Meeting, Orlando, FL, April 14-18, 2010. *J AAPOS.* 2010; **14(1)**: e24-e25.
22. **Hampp C**, Kauf TL, Saidi A, Winterstein AG. Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab from the Perspective of a Southern US Medicaid Agency. ISPOR

12th Annual European Congress, Paris, France, October 24-27, 2009. *Value Health*. 2009; **12(7)**: A301. **Best Student Research Poster Presentation**

23. **Hampp C**, Winterstein AG. Seasonal versus Needs-Based Immunization Schedules – the Example of RSV. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009. *Value Health*. 2009; **12(7)**: A307. **Finalist, Poster Competition**
24. **Hampp C**, Winterstein A. Validation of the National Respiratory and Enteric Virus Surveillance System for the Detection of Respiratory Syncytial Virus Seasons. 25th International Conference on Pharmacoepidemiology and Therapeutic risk Management. Providence, Rhode Island. August 16-19, 2009. *Pharmacoepidemiol Drug Saf*. 2009; **18**:S118. (oral presentation)
25. Winterstein AG, **Hampp C**, Saidi A. Effectiveness of Palivizumab in Medicaid infants. 25th International Conference on Pharmacoepidemiology and Therapeutic risk Management. Providence, Rhode Island. August 16-19, 2009. *Pharmacoepidemiol Drug Saf*. 2009; **18**:S97-98. (oral presentation)
26. **Hampp C**, Winterstein AG, Saidi A. Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab from the Perspective of Florida Medicaid. 22nd annual research showcase, Feb, 19, 2009, Levitt Division, College of Pharmacy, University of Florida. **Winner, Oral Competition**
27. Bush SE, **Hampp C**, Lottenberg LL, LeClaire AC. Erythropoiesis-Stimulating Agent Exposure and Incidence of Venous Thromboembolism in High-Risk Trauma Patients Receiving Enoxaparin Prophylaxis. Society of Critical Care Medicine 38th Critical Care Congress, Jan 31 - Feb 4 2009, Nashville, TN. *Crit Care Med*. 2008; **36(suppl)**: A51.
28. Dee A, Kelly B, **Hampp C**, Kimberlin C. Improving and Reducing First Dose Antibiotic Turnaround Time for Pediatric Patients. American Society of Health-System Pharmacists Midyear Clinical Meeting, December 6, 2008, Orlando, FL
29. Bush S, LeClaire A, **Hampp C**, Lottenberg L. Once-Daily versus Twice-Daily Enoxaparin for Venous Thromboembolism Prophylaxis in High-Risk Trauma Patients. American Association for the Surgery of Trauma 2008 Annual Meeting, Sept 24-27, Maui, HI
30. **Hampp C**, Winterstein AG. Palivizumab Utilization and Compliance with Recommendations in Florida. 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 17-20, 2008, Copenhagen, Denmark. *Pharmacoepidemiol Drug Saf*. 2008; **17**:S25 (oral presentation). **Best Drug Utilization Abstract Submitted by a Student**
31. **Hampp C**, Winterstein AG, Saidi A. Role of Age in Respiratory Syncytial Virus Infection Risk – Recommendations for Palivizumab Utilization. 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 17-20, 2008, Copenhagen, Denmark. *Pharmacoepidemiol Drug Saf*. 2008; **17**: S186
32. **Hampp C**, Schauff M, Saidi A, Winterstein AG. Changes in Respiratory Syncytial Virus Related Hospitalizations and Prevention in Infants with Cardiac Anomalies. 57th Annual Scientific Session, American College of Cardiology, March 31 2008, Chicago, IL
33. **Hampp C**, Winterstein AG, Saidi A. Palivizumab Utilization and Compliance – The Current State of Respiratory Syncytial Virus Prophylaxis in Florida. 21st annual research showcase, Feb, 21, 2008, College of Pharmacy, University of Florida. **Winner, Best Poster Award**
34. **Hampp C**, Winterstein AG, Saidi A, Schauff M. Palivizumab Utilization and Hospitalizations Related to Respiratory Syncytial Virus Infections Among Florida Medicaid Recipients. 23rd

International Conference on Pharmacoepidemiology. August 19-22, 2007. Quebec City, Canada. *Pharmacoepidemiol Drug Saf.* 2007; **16**:S170

35. **Hampp C**, Hartzema AG, Kauf TL. The Impact of Rimonabant on Obesity-Related Diseases and Quality of Life: A Cost - Utility Analysis. 22nd International Conference on Pharmacoepidemiology Aug. 27, 2006, Lisbon, Portugal. *Pharmacoepidemiol Drug Saf.* 2006; **15**:S279
36. **Hampp C**. Cost-Utility Analysis of Rimonabant in the Treatment of Obesity., International Society for Pharmacoeconomics and Outcomes Research Annual Meeting 2006, May 22, 2006, Philadelphia, PA. *Value Health.* **9(3)**, A90.
37. **Hampp C**, Hartzema AG. Cost-Utility of Rimonabant in the Treatment of Obesity. Oral Competition, 19th annual research showcase, Levitt Division, Feb, 23, 2006, College of Pharmacy, University of Florida (oral presentation) **Finalist, Oral Competition**
38. Mueller M, **Hampp C**, Mukherjee K, Ried LD. Predictors of Subjective Well-Being in a Population of Patients with Hypertension and Coronary Artery Disease. *J Amer Pharm Assoc.* 2006; **46(2)**: 271.

Reports

1. Winterstein AG, **Hampp C**, Kubilis PS. Effectiveness of palivizumab in older premature infants. Report to the Agency for Healthcare Administration, Division of Medicaid. June 2010 (15 pages)
2. **Hampp C**, Winterstein AG. Utility of current surveillance systems to detect respiratory syncytial virus seasons and implications for Immunoprophylaxis. Report to the Agency for Healthcare Administration, Division of Medicaid. June 2010 (92 pages)
3. **Hampp C**, Winterstein AG. RSV Seasonality and Numbers Needed to Treat with Palivizumab in Florida Medicaid. Report to the Agency for Healthcare Administration, Florida Department of Health. March 2009 (11 Pages)
4. Winterstein AG, **Hampp C**, Saidi A. Palivizumab Utilization, Effectiveness and Cost among Florida Medicaid Recipients. Final Report to the Agency for Healthcare Administration, Florida Department of Health. July 2008 (84 pages)

Invited Presentations

1. U.S. Post-Marketing Drug Safety. Advance Pharmacy Preceptor Training Workshop Faculty of Pharmacy, Chiang Mai University Chiang Mai, Thailand, March 16, 2018. (online)
2. Post Marketing Risk Analysis and Mitigation Strategies. Presentation during PHRMRA 528 - Medical Risk Analysis and Management course, University of Washington, Seattle, WA, November 7, 2017.
3. Prospective Surveillance of AMI Events in New Users of Saxagliptin. Ninth Annual Sentinel Initiative Public Workshop. Washington, D.C., February 2, 2017.

4. FDA Guidance: Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using EHRs. Drug Information Association Pharmacovigilance and Risk Management Strategies Conference. Washington, D.C., January 23, 2017.
5. Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion - United States, 2008–2015. Presentation to FDA's Opioid Task Force. December 14, 2016.
6. Post Marketing Risk Analysis and Mitigation Strategies. Presentation during PHRMRA 528 - Medical Risk Analysis and Management course, University of Washington, Seattle, WA, November 8, 2016.
7. Post Marketing Risk Analysis and Mitigation Strategies. Presentation during PHRMRA 528 - Medical Risk Analysis and Management course, University of Washington, Seattle, WA, February 18, 2016.
8. Use of Prescription Drug Samples in the United States and Implications for Pharmacoepidemiologic Studies, presentation at graduate seminar, Harrison School of Pharmacy, Auburn University, October 2, 2015, online.
9. Measures of Association, Lecture to Nursing PhD students at the University of North Dakota, September 4, 2012, online.
10. Regulatory Basis of Postmarketing Drug Safety, Lecture to students in the University of Florida Masters in Pharmacy Regulation program, November 14, 2011, online.
11. Respiratory Syncytial Virus Infections and Prophylaxis in Florida, Pediatric Grand Rounds, Shands Hospital at the University of Florida, November 21, 2008.

Presentations before Federal Advisory Committees

1. FDA-Reviewed Observational Studies on GLP-1 Analogs. Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Hyattsville, Maryland, September 11, 2014.
2. Analysis of Cancer Incidence Observed in Liraglutide Clinical Trials. Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Hyattsville, Maryland, September 11, 2014.
3. Duration of Use – Antiobesity Drugs. Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Silver Spring, Maryland, March 28/29, 2012.
4. Hospitalized Rhabdomyolysis with Combined Statin/Fibrate Use - Observational Evidence Submitted by the Sponsor in the Context of the Trilipix Postmarketing Requirement. Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Silver Spring, Maryland, May 19, 2011.

Workshops

- 2014 - 2017: “Practical skills in protocol writing and computer programming,” ICPE Annual Meeting

Professional Activities

Selected Peer Review Activities

- Annals of Internal Medicine*
- Archives of Disease in Childhood
- Diabetes, Obesity and Metabolism
- Journal of Pediatrics
- Journal of the American Pharmacists Association
- Medical Care
- Pediatrics
- Pharmacoepidemiology and Drug Safety*
- Value in Health

- ISPOR Annual Meeting 2010, 2011 (abstract reviewer)
- ICPE Annual Meeting 2010 - 2018 (abstract reviewer + newcomer track in 2014)
- North American Congress of Epidemiology 2011 (abstract reviewer)

Active Professional Memberships

- Since 2010 UF Alumni Association
- Since 2007 SER, Society for Epidemiologic Research
- Since 2006 ISPE, International Society for Pharmacoepidemiology:
 - Since 2014 Member, Education Committee
 - Since 2015 CDER Liaison to ISPE Board of Directors
 - Since 2016 Member, Core Scientific Program Committee

- Since 2005 ISPOR, International Society for Pharmacoeconomics and Outcomes Research
- Since 2002 DPhG, German Pharmaceutical Society

*recognized as outstanding peer reviewer